Division of Hematology/Oncology


faculty photo

Roger B Cohen

Professor of Medicine at the Hospital of the University of Pennsylvania
Associate DIrector Clinical Research Abramson Cancer Center, Abramson Cancer Center
Chief Clinical Research Officer, Abramson Cancer Center
Senior Director, Regulatory and Quality Assurance Unit, Translational Research Program, PSOM, ACC
Department: Medicine

Contact information
Division of Hematology-Oncology
Department of Medicine
University of Pennsylvania School of Medicine
Philadelphia, PA 19104
Office: 2156624469
A.B. (Biochemical Sciences)
Harvard College (magna cum laude), 1976.
M.D. (Medicine)
Harvard Medical School, 1980.
Post-Graduate Training
Intern in Medicine, Mount Sinai Hospital, New York, NY, 1980-1981.
Resident in Medicine, Mount Sinai Hospital, New York, NY, 1981-1982.
Research Fellow, Gene Structure & Expression, Sloan-Kettering Cancer Research Institute, New York, NY, 1982-1985.
Clinical Fellowship in Hematology, Mount Sinai Hospital, New York, NY, 1985-1986.
Fellowship, Laboratory of Molecular Hematology, NHLBI, Bethesda, MD, 1986-1989.
Clinical Fellowship, Medical Oncology, National Cancer Institute, Bethesda, MD, 1991-1993.
Internal Medicine, ABIM, 1984.
Hematology, ABIM, 1986.
Medical Oncology, ABIM, 1993.
Medical Oncology, ABIM (re-certified), 2005.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Chiorean EG, Hurwitz HI, Cohen RB, Schwartz JD, Dalal RP, Fox FE, Gao L, Sweeney CJ.: Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors. Ann Oncol March 2015

Kaczmar John M, Tan Kay See, Heitjan Daniel F, Lin Alexander, Ahn Peter H, Newman Jason G, Rassekh Christopher H, Chalian Ara A, O'Malley Bert W, Cohen Roger B, Weinstein Gregory S: HPV-related oropharyngeal cancer: risk factors for treatment failure in patients managed with primary surgery (TORS). Head & neck Sep 2014.

Mateo J, Berlin J, de Bono J S, Cohen R B, Keedy V, Mugundu G, Zhang Lianglin, Abbattista A, Davis C, Gallo Stampino C, Borghaei H: A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors. Cancer chemotherapy and pharmacology 74(5): 1039-46, Sep 2014.

Infante Jeffrey R, Dees E Claire, Olszanski Anthony J, Dhuria Shyeilla V, Sen Suman, Cameron Scott, Cohen Roger B: Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 32(28): 3103-10, Aug 2014.

Lukens J Nicholas, Lin Alexander, Gamerman Victoria, Mitra Nandita, Grover Surbhi, McMenamin Erin M, Weinstein Gregory S, O'Malley Bert W, Cohen Roger B, Orisamolu Abimbola, Ahn Peter H, Quon Harry: Late consequential surgical bed soft tissue necrosis in advanced oropharyngeal squamous cell carcinomas treated with transoral robotic surgery and postoperative radiation therapy. International journal of radiation oncology, biology, physics 89(5): 981-8, Aug 2014.

Bowles Daniel W, Senzer Neil, Hausman Diana, Peterson Scott, Vo Alex, Walker Luke, Cohen Roger B, Jimeno Antonio: A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck. Investigational new drugs 32(6): 1197-203, Jun 2014.

von Mehren Margaret, Britten Carolyn D, Pieslor Peter, Saville Wayne, Vassos Artemios, Harris Sarah, Galluppi Gerald R, Darif Mohamed, Wainberg Zev A, Cohen Roger B, Leong Stephen: A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors. Investigational new drugs 32(3): 518-25, Jun 2014.

Jänne Pasi A, Cohen Roger B, Laird A Douglas, Macé Sandrine, Engelman Jeffrey A, Ruiz-Soto Rodrigo, Rockich Kevin, Xu Jianbo, Shapiro Geoffrey I, Martinez Pablo, Felip Enriqueta: Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 9(3): 316-23, Mar 2014.

Naing, A, Cohen, R, Dy, GK, Hong, DS, Dyster, L, Hangauer, DG, Kwan, R, Fetterly, G, Kurzrock, R, Adjei, AA: A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies. investigational new drugs 31(4): 967-973, AUG 2013.

Weinblatt Michael E, Moreland Larry W, Westhovens Rene, Cohen Roger B, Kelly Sheila M, Khan Nader, Pappu Ramesh, Delaet Ingrid, Luo Allison, Gujrathi Sheila, Hochberg Marc C: Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program. The Journal of rheumatology 40(6): 787-97, Jun 2013.

back to top
Last updated: 05/19/2015
The Trustees of the University of Pennsylvania

Clinical Briefings Blog Spot

Penn MD Forum title with Penn Medicine Shield and Twitter